Cite
Caocci G, Mulas O, Mantovani D, et al. Ruxolitinib does not impair humoral immune response to COVID-19 vaccination with BNT162b2 mRNA COVID-19 vaccine in patients with myelofibrosis. Ann Hematol. 2021;doi: 10.1007/s00277-021-04613-w.
Caocci, G., Mulas, O., Mantovani, D., Costa, A., Galizia, A., Barabino, L., Greco, M., Murru, R., & La Nasa, G. (2021). Ruxolitinib does not impair humoral immune response to COVID-19 vaccination with BNT162b2 mRNA COVID-19 vaccine in patients with myelofibrosis. Annals of hematology, . https://doi.org/10.1007/s00277-021-04613-w
Caocci, Giovanni, et al. "Ruxolitinib does not impair humoral immune response to COVID-19 vaccination with BNT162b2 mRNA COVID-19 vaccine in patients with myelofibrosis." Annals of hematology vol. (2021). doi: https://doi.org/10.1007/s00277-021-04613-w
Caocci G, Mulas O, Mantovani D, Costa A, Galizia A, Barabino L, Greco M, Murru R, La Nasa G. Ruxolitinib does not impair humoral immune response to COVID-19 vaccination with BNT162b2 mRNA COVID-19 vaccine in patients with myelofibrosis. Ann Hematol. 2021 Jul 24; doi: 10.1007/s00277-021-04613-w. Epub 2021 Jul 24. PMID: 34302519; PMCID: PMC8308065.
Copy
Download .nbib
